Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6atac small nuclear 19, pseudogene (RNU6ATAC19P) is classified as a pseudogene—a DNA sequence resembling a gene but typically nonfunctional due to mutations, deletions, or insertions[1][4][6]. It shares sequence similarity with functional U6atac small nuclear RNA genes, which are paralogs of U6 snRNA and participate in the catalytic core of the minor (U12-dependent) spliceosome involved in pre-mRNA splicing[5]. However, this particular locus (the RNU6ATAC19P pseudogene) is not thought to produce a functional RNA product or protein and is not considered a therapeutic target in drug development or disease[1]. Pseudogenes can occasionally have regulatory roles—such as involvement in RNA interference pathways or acting as miRNA decoys in other cases, but there is no specific evidence that RNU6ATAC19P has such functions[4][6]. The entry is also technically “incorrect” as a target because it is a pseudogene and not an active, functional molecule; therefore, it should not be used as a drug or research “target”[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 19, pseudogene (RNU6ATAC19P).